Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Sorry? So yeah, what's your point?

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jan 19, 2022 11:30am

64 Views

Post# 34332868

RE:Sorry? So yeah, what's your point?

You do know there is difference between negotiating for an agreement and actually signing or having it approved and finalized.

So yes it seems you are missing something.

"You can't say the same thing 5 different times and expect a good response from intelligent shareholders."

Actually I "assumed" I was speaking to one, don't dissappoint me.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports